Alkermes' Q4 Earnings & Revenues Surpass Estimates, Stock Up
ALKS reports better-than-expected fourth-quarter 2024 results. Net sales of proprietary products increase year over year. Shares rise.
Alkermes price target raised to $38 from $35 at TD Cowen
TD Cowen analyst Joseph Thome raised the firm’s price target on Alkermes (ALKS) to $38 from $35. The firm said total Q4 revenue came in above ...
Alkermes PLC (ALKS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Debt-Free Milestone
Alkermes PLC (ALKS) reports over $1.5 billion in revenue, retires all debt, and outlines strategic plans for 2025 amidst ...
Alkermes targets $310M-$340M adjusted EBITDA amid LYBALVI growth and orexin pipeline expansion
For 2025, Alkermes plans to generate over $200 million in EBITDA while advancing its orexin program, particularly ALKS 2680, which is enrolling Phase 2 studies for narcolepsy. These studies are ...